Navigation Links
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Date:10/27/2011

SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011.

"We achieved over $200 million in revenues this quarter, which reflects the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I'm also pleased that our Board of Directors recently authorized a $300 million share repurchase program, which has already begun to return additional value to our shareholders."

Total revenues for the quarter ended September 30, 2011 were $201.7 million, up from $168.6 million for the quarter ended September 30, 2010. Net income for the quarter ended September 30, 2011 was $84.4 million or $1.45 per basic share, compared to $39.7 million or $0.70 per basic share for the same quarter in 2010. Gross margin from sales was $178.3 million for the quarter ended September 30, 2011, compared to $148.1 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended September 30, 2011 were $100.8 million, compared to $99.3 million for the quarter ended September 30, 2010.

Financial Results for the Three Months Ended September 30, 2011Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedSeptember 30,20112010PercentageChangeCardiopulmonary products:Remodulin

$

114,918$

109,5844.9%Tyvaso

66,33048,71736.2%Adcirca

19,7729,93599.0%Other

722339113.0%Total net revenues

$

201,742$

168,57519.7%Revenues for the quarter ended September 30, 2011 increased by $33.2 million, compared to the quarter ended September 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our produc
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
2. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
3. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
4. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
5. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
6. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
7. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
8. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
9. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
10. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
11. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/15/2014)... Denmark , Dec. 15, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  This interim analysis consists ... anticipated total enrollment in the study, completing all ...
(Date:12/13/2014)... Rockville, Maryland (PRWEB) December 12, 2014 ... Maryland, today announced its new name: Therabron Therapeutics ... words therapy and bronchioles (a type of structure in ... incorporating the company’s mission to develop novel protein therapeutics ... board of directors decided to change the name to ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of person to staff customer support centers. These specialists must ... of a complicated computer system, and then be able to ... Finding these very talented people is not an easy task, ... high degree of technical aptitude. But there is more to ...
... of Fiserv, Inc. has announced the launch ... self-funded health care market. , , Fiserv Health ... administration services for self-funded medical, dental, vision and disability ... now has an integrated suite of medical management programs ...
... named to the top five in the "specialty niche" ... KLAS , a provider of healthcare information technology (HIT) ... score for all time and attendance system vendors scoring ... Performance award. , , KLAS provides the ...
Cached Biology Technology:Hope For Some U.S. Tech Workers 2Hope For Some U.S. Tech Workers 3Fiserv Launches Avidyn Health to Target Healthcare Costs 2API Receives Top 5 Recognition in "Best In KLAS" Awards 2
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... study to conserve and restore endangered horse mussel reefs ... University,s marine research and outreach centre in Portaferry in ... Biological Sciences, will provide scientific and technological research to ... restore it. Horse mussel reefs are important to ...
... one of the major threats to biodiversity and in ... human health. For their effective management it is important ... highest risk of being invaded. The first map ... Union was published in the Wiley-Blackwell journal Diversity ...
... Amsterdam, The Netherlands, January 22, 2009 A growing ... to delay age-related cognitive decline, including in some cases ... published in the January 2009 issue of the ... PhD, of the Center for Cellular Neurobiology; Neurodegeneration Research ...
Cached Biology News:Queen's University Belfast works to save Strangford horse mussels 2
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: